JP2002512026A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002512026A5 JP2002512026A5 JP2000544789A JP2000544789A JP2002512026A5 JP 2002512026 A5 JP2002512026 A5 JP 2002512026A5 JP 2000544789 A JP2000544789 A JP 2000544789A JP 2000544789 A JP2000544789 A JP 2000544789A JP 2002512026 A5 JP2002512026 A5 JP 2002512026A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- composition
- compound according
- vector
- streptococcus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 description 30
- 239000000203 mixture Substances 0.000 description 14
- 150000004676 glycans Chemical class 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 229940124856 vaccine component Drugs 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9808327.2A GB9808327D0 (en) | 1998-04-20 | 1998-04-20 | Antidiotypic compounds |
| GB9808327.2 | 1998-04-20 | ||
| PCT/IB1999/000799 WO1999054457A1 (en) | 1998-04-20 | 1999-04-20 | Vaccine formulations comprising antiidiotypic antibodies which immunologically mimic group b streptococcal carbohydrates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009123637A Division JP2009179645A (ja) | 1998-04-20 | 2009-05-21 | Ｂ群連鎖球菌の糖質を免疫学的に模倣する抗イディオタイプ抗体を含むワクチン処方物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002512026A JP2002512026A (ja) | 2002-04-23 |
| JP2002512026A5 true JP2002512026A5 (enExample) | 2006-06-15 |
| JP4446601B2 JP4446601B2 (ja) | 2010-04-07 |
Family
ID=10830608
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000544789A Expired - Fee Related JP4446601B2 (ja) | 1998-04-20 | 1999-04-20 | Ｂ群連鎖球菌の糖質を免疫学的に模倣する抗イディオタイプ抗体を含むワクチン処方物 |
| JP2009123637A Withdrawn JP2009179645A (ja) | 1998-04-20 | 2009-05-21 | Ｂ群連鎖球菌の糖質を免疫学的に模倣する抗イディオタイプ抗体を含むワクチン処方物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009123637A Withdrawn JP2009179645A (ja) | 1998-04-20 | 2009-05-21 | Ｂ群連鎖球菌の糖質を免疫学的に模倣する抗イディオタイプ抗体を含むワクチン処方物 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US6676938B1 (enExample) |
| EP (1) | EP1071763B1 (enExample) |
| JP (2) | JP4446601B2 (enExample) |
| AT (1) | ATE425251T1 (enExample) |
| CA (1) | CA2325566C (enExample) |
| CY (1) | CY1109140T1 (enExample) |
| DE (1) | DE69940545D1 (enExample) |
| GB (1) | GB9808327D0 (enExample) |
| WO (1) | WO1999054457A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1181058A2 (de) * | 1999-05-27 | 2002-02-27 | Max-Delbrück-Centrum Für Molekulare Medizin | Vakzine gegen konformationsabhängige antigene sowie gegen antigene, die keine oder nicht ausschliesslich proteine oder peptide sind |
| WO2002034771A2 (en) | 2000-10-27 | 2002-05-02 | Chiron Srl | Nucleic acids and proteins from streptococcus groups a & b |
| WO2004018646A2 (en) * | 2002-08-26 | 2004-03-04 | Chiron Corporation | Conserved and specific streptococcal genomes |
| EP1648500B1 (en) | 2003-07-31 | 2014-07-09 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic compositions for streptococcus pyogenes |
| US8945589B2 (en) | 2003-09-15 | 2015-02-03 | Novartis Vaccines And Diagnostics, Srl | Immunogenic compositions for Streptococcus agalactiae |
| EP1784211A4 (en) | 2004-07-29 | 2010-06-30 | Novartis Vaccines & Diagnostic | IMMUNOGENIC COMPOSITIONS FOR GRAMPOSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE |
| AU2005294275B2 (en) * | 2004-10-08 | 2012-09-13 | Glaxosmithkline Biologicals S.A. | Immunogenic and therapeutic compositions for Streptococcus pyogenes |
| US20090104218A1 (en) * | 2004-12-22 | 2009-04-23 | J. Craig Venter Institute | Group B Streptococcus |
| US8062644B2 (en) | 2005-02-18 | 2011-11-22 | Novartis Vaccines & Diagnostics Srl. | Immunogens from uropathogenic Escherichia coli |
| WO2008020335A2 (en) * | 2006-06-09 | 2008-02-21 | Novartis Ag | Immunogenic compositions for streptococcus agalactiae |
| WO2008020330A2 (en) | 2006-08-16 | 2008-02-21 | Novartis Ag | Immunogens from uropathogenic escherichia coli |
| AU2007348285A1 (en) * | 2006-10-30 | 2008-09-12 | Novartis Ag | Immunogenic and therapeutic compositions for streptococcus pyogenes |
| AU2008299376B2 (en) | 2007-09-12 | 2013-02-28 | Glaxosmithkline Biologicals S.A. | GAS57 mutant antigens and GAS57 antibodies |
| NZ586430A (en) | 2007-12-21 | 2012-09-28 | Novartis Ag | Mutant forms of streptolysin o (slo) |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP3431485B2 (en) | 2010-10-01 | 2024-09-04 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2763701B1 (en) | 2011-10-03 | 2018-12-19 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
| CA2892529C (en) | 2012-11-26 | 2023-04-25 | Moderna Therapeutics, Inc. | Terminally modified rna |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EA201690675A1 (ru) | 2013-10-03 | 2016-08-31 | Модерна Терапьютикс, Инк. | Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности |
| WO2019199850A1 (en) | 2018-04-10 | 2019-10-17 | Gary A. Zwick, Trustee Of The Everest Trust Uta April 20, 2017 | Spinal interbody cage comprising top and bottom faces with mesh structures, pillars and slots |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5476784A (en) * | 1993-04-06 | 1995-12-19 | Rice; Peter A. | Gonococcal anti-idiotypic antibodies and methods and compositions using them |
| WO1997045449A1 (en) * | 1996-05-29 | 1997-12-04 | Derek Nigel John Hart | Dendritic cell receptor |
| US6140091A (en) * | 1997-06-20 | 2000-10-31 | Boston Biomedical Research Institute | Anti-idiotype vaccines to elicit catalytic antibodies |
| AU755343B2 (en) * | 1997-12-31 | 2002-12-12 | Montana State University-Bozeman | A method of isolating a peptide which immunologically mimics microbial carbohydrates including group B streptococcal carbohydrates and the use thereof in a vaccine |
-
1998
- 1998-04-20 GB GBGB9808327.2A patent/GB9808327D0/en not_active Ceased
-
1999
- 1999-04-20 DE DE69940545T patent/DE69940545D1/de not_active Expired - Lifetime
- 1999-04-20 AT AT99914725T patent/ATE425251T1/de active
- 1999-04-20 JP JP2000544789A patent/JP4446601B2/ja not_active Expired - Fee Related
- 1999-04-20 US US09/673,867 patent/US6676938B1/en not_active Expired - Fee Related
- 1999-04-20 CA CA2325566A patent/CA2325566C/en not_active Expired - Fee Related
- 1999-04-20 EP EP99914725A patent/EP1071763B1/en not_active Expired - Lifetime
- 1999-04-20 WO PCT/IB1999/000799 patent/WO1999054457A1/en not_active Ceased
-
2003
- 2003-11-07 US US10/703,886 patent/US6900302B2/en not_active Expired - Fee Related
-
2009
- 2009-05-21 JP JP2009123637A patent/JP2009179645A/ja not_active Withdrawn
- 2009-06-09 CY CY20091100604T patent/CY1109140T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002512026A5 (enExample) | ||
| CA2325566A1 (en) | Vaccine formulations comprising antiidiotypic antibodies which immunologically mimic group b streptococcal carbohydrates | |
| Ambühl et al. | A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity | |
| US6849259B2 (en) | Polyclonal antibody composition for treating allergy | |
| US20250242010A1 (en) | Compositions and methods for making and using thermostable immunogenic formulations with increased compatibility of use as vaccines against one or more pathogens | |
| JP2006516639A5 (enExample) | ||
| JP2000516200A (ja) | ウシの呼吸病に対するポリヌクレオチドワクチン処方 | |
| CA2683772C (en) | New virulence factors of streptococcus pneumoniae | |
| JP2002528123A5 (enExample) | ||
| AU707083B2 (en) | Inducing antibody response against self-proteins with the aid of foreign T-cell epitopes | |
| US20240316167A1 (en) | Treatment of urticaria | |
| JPH07506374A (ja) | う蝕予防用合成ペプチドワクチン | |
| US6129922A (en) | Methods for adjuvant free hepatitis A virus vaccination | |
| JP2003514028A (ja) | ワクチンとしての抗体の新たな使用 | |
| CN103724413B (zh) | 旋毛虫副肌球蛋白b细胞抗原表位8a1及其应用 | |
| EP3804748A1 (en) | Phosphorylated polypeptide antigen vaccine, preparation method therefor and application thereof | |
| JPS6117523A (ja) | 淋疾のための広域スペクトルワクチン | |
| JP2002516662A5 (enExample) | ||
| US20170035878A1 (en) | Multi-Functional Mucosal Vaccine Platform | |
| CN120500351A (zh) | 呼吸道合胞病毒mRNA疫苗 | |
| JP2003519089A (ja) | 肺炎球菌表面型蛋白質配合ワクチン | |
| JP2001517447A (ja) | Ｂ型肝炎ウイルスポリペプチド | |
| KR100905249B1 (ko) | Ｄｎａ와 항원의 조합에 의해 효능이 증강된 백신포뮬레이션 | |
| Uijen et al. | Intradermal administration of the pneumococcal conjugate vaccine in mice results in lower antibody responses as compared to intramuscular administration | |
| CN117379424B (zh) | 米拉贝隆在制备预防和/或治疗免疫系统功能障碍药物中的应用 |